- The deal expands VION’s regulated large molecule bioanalytical and CMC capabilities, including pharmacokinetic and immunogenicity testing
- Prolytix’s reagents and diagnostic inputs deepen VION’s position in IVD raw materials and OEM support
- The acquisition marks VION’s seventh deal since 2023 as it builds an integrated life sciences platform
VION Biosciences, backed by Iron Path Capital, has closed its acquisition of Prolytix, a provider of regulated bioanalytical and CMC services, research reagents and custom sample collection products.
Headquartered in Shaker Heights, Ohio, VION is a life sciences tools and services company building integrated capabilities across research, diagnostics and drug development workflows. The acquisition supports VION’s strategy to connect specialized scientific capabilities across those areas, strengthening two complementary parts of the business: regulated large molecule services for biopharma customers and workflow-critical reagents, consumables and diagnostic inputs.
The deal expands VION’s regulated large molecule bioanalytical and CMC capabilities, including pharmacokinetic, anti-drug antibody and immunogenicity testing, biomarker assays, method development and validation, and release and stability testing. Combined with Cellular Technology Limited’s functional immune monitoring capabilities, the added services help VION support customers seeking connected immunogenicity, bioanalytical, biomarker and regulated testing. The deal also expands VION’s products and materials offering through research reagents, plasma and coagulation-related proteins, IVD and point-of-care reagent capabilities, and custom sample collection devices, deepening the company’s position in diagnostic workflow inputs and OEM support alongside Ansh Labs and other VION capabilities.
Since 2023, VION has completed seven acquisitions aimed at building a more integrated enterprise across biopharmaceutical research, drug development, clinical testing and diagnostic workflows.
Editor’s note: This news brief was produced with the assistance of artificial intelligence.